Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Cholangiocarcinoma is a heterogenous malignancy with various classifications based on location, morphological features, histological features, and actionable genetic mutations. Intrahepatic cholangiocarcinoma (ICC), which arises in and proximal to second order bile ducts, is the second most common primary liver malignancy after hepatocellular carcinoma. In this review, we will discuss ICC risk factors, precursor lesions, various growth, anatomic, morphologic, and histologic classifications, rare variants, and differential diagnoses.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00261-024-04732-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: The accuracy of CA19-9 detection results is very important for the early detection and treatment of pancreatic cancer, cholangiocarcinoma and other malignant tumors. At present, endogenous substances such as heterophilic antibodies will cause interference in the commonly used detection method is electrochemilumines-cence immunoassay, resulting in inaccurate results and affecting clinical diagnosis and treatment.
Methods: This paper reports a patient with an abnormal increase in serum CA19-9 level to explore how to accurately identify non-specific interference and anti-interference countermeasures.
ASO Visual Abstract: Real-World Single-Center Experience with Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab in Borderline Resectable Cholangiocarcinoma.
Ann Surg Oncol
September 2025
Department of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN, USA.
Central Hepatectomy as an Alternative: A Comparative Study with Conventional Major Hepatectomy for Perihilar Cholangiocarcinoma.
Ann Surg Oncol
September 2025
Department of Hepatobiliary-Pancreatic Surgery, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Background: Right-sided hepatectomy (RH) is the standard surgical approach for perihilar cholangiocarcinoma (PHC) due to anatomical considerations but is associated with a high risk of post-hepatectomy liver failure (PHLF). Left-sided hepatectomy (LH) and central hepatectomy (CH) have been proposed as alternative strategies to preserve liver function, but the feasibility and outcomes of CH have not been sufficiently investigated. CH allows for greater preservation of liver parenchyma, potentially reducing the risk of PHLF.
View Article and Find Full Text PDFPeri-hilar cholangiocarcinoma: results from the UK nationwide CAPBIL study.
HPB (Oxford)
August 2025
Nottingham University Hospitals NHS Trust, Nottingham, UK. Electronic address:
Background: The role of liver transplantation as a treatment option for de novo resectable peri-hilar cholangiocarcinoma (pCCA) is controversial. This study investigated the outcomes following resection of early-stage pCCA in the UK.
Methods: Patients undergoing resection for pCCA between 2014 and 2022 across 22 UK centres were included.
Emerging HER2 Targeting Immunotherapy for Cholangiocarcinoma.
Oncol Res
September 2025
Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection & Graduate School of Medical Sciences, Kumamoto University 2-2-1 Honjo, Chuo-ku, Kumamoto, 860-0811, Japan.
Cholangiocarcinoma (CCA) is a fatal bile duct malignancy. CCA is intrinsically resistant to standard chemotherapy, responds poorly to it, and has a poor prognosis. Effective treatments for cholangiocarcinoma remain elusive, and a breakthrough in CCA treatment is still awaited.
View Article and Find Full Text PDF